MyFinsight
Home
Blog
About
Contact
Download
Download image
BRUKINSA
$3,928,489K
Tislelizumab
$737,304K
XGEVA
$305,979K
BLINCYTO
$104,224K
Other
$83,691K
KYPROLIS
$74,974K
POBEVCY
$47,400K
Amgen Royalty Revenue
$40,733K
Novartis Broad Markets
Revenue
$17,598K
Collaboration Other
$2,641K
Product
$5,282,061K
Collaboration
$60,972K
Total revenues
$5,343,033K
Gross profit
$4,674,493K
Cost of sales -
product-Product
$668,540K
Income (loss) from
operations
$447,136K
Interest income
$70,505K
Total operating
expenses
$4,227,357K
Income (loss) before
income taxes
$416,854K
Interest expense
$58,234K
Other (expense)
income, net
-$42,553K
Research and development
$2,145,868K
Selling, general and
administrative
$2,081,489K
Net income (loss)
$286,933K
Income tax expense
$129,921K
Back
Back
Income Statement
source: myfinsight.com
BeOne Medicines Ltd. (ONC)
BeOne Medicines Ltd. (ONC)